0000000000082722

AUTHOR

Banumathy Gowrishankar

showing 2 related works from this author

Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.

2016

e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...

OncologyCancer Researchmedicine.medical_specialtySunitinibbusiness.industryDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomaInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma

2015

4552 Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease (PRD) with progression as the best response. T...

Cancer ResearchSunitinibbusiness.industryChromosomeDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomamedicineCancer researchIn patientbusinessmedicine.drug
researchProduct